Passage Bio, Inc. announced that the board of directors and Bruce Goldsmith, Ph.D. have mutually agreed that Dr. Goldsmith will step down as president and a member of the board, effective immediately. The board has appointed Edgar B. (Chip) Cale, the current general counsel and corporate secretary, as interim CEO. Dr. Goldsmith will serve as a strategic advisor to management and the board for a transition period.

Maxine Gowen, Ph.D., the company's chairwoman, has assumed the role of interim executive chairwoman of the board. The board has initiated a search for a permanent CEO. Mr. Cale has been at Passage Bio since September 2019.

Prior to joining the company, Mr. Cale spent more than twenty years at GlaxoSmithkline, most recently as Senior Vice President of Legal Corporate Functions, which included legal support for global business development and corporate functions. At GSK, he also served as General Counsel of GSK's Vaccine division. Mr. Cale has a BA in Biology from the University of Pennsylvania, and a JD from University of California at Berkeley.